Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul 29:9:47.
doi: 10.1186/1745-6215-9-47.

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

Adnan Aydiner  1 , Faruk Tas
Affiliations

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

Adnan Aydiner et al. Trials. .

Abstract

Objective: It was aimed to review the literature and make a meta-analysis of the trials on both upfront, switching, and sequencing anastrozole in the adjuvant treatment of early breast cancer.

Methods: The PubMed, ClinicalTrials.gov and Cochrane databases were systematically reviewed for randomized-controlled trials comparing anastrozole with tamoxifen in the adjuvant treatment of early breast cancer.

Results: The combined hazard rate of 4 trials for event-free survival (EFS) was 0.77 (95%CI: 0.70-0.85) (P < 0.0001) for patients treated with anastrozole compared with tamoxifen. In the second analysis in which only ITA, ABCSG 8, and ARNO 95 trials were included and ATAC (upfront trial) was excluded, combined hazard rate for EFS was 0.64 (95%CI: 0.52-0.79) (P < 0.0001). In the third analysis including hazard rate for recurrence-free survival (excluding non-disease related deaths) of estrogen receptor-positive patients for ATAC trial and hazard rate for EFS of all patients for the rest of the trials, combined hazard rate was 0.73 (95%CI: 0.65-0.81) (P < 0.0001).

Conclusion: Anastrozole appears to have superior efficacy than tamoxifen in the adjuvant hormonal treatment of early breast cancer. Until further clinical evidence comes up, aromatase inhibitors should be the initial hormonal therapy in postmenopausal early breast cancer patients and switching should only be considered for patients who are currently receiving tamoxifen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram for identification of trials for meta-analysis.
Figure 2
Figure 2
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were included. aFor ATAC trial, HR for recurrence free survival was included in the model. Test for heterogeneity (Q) = 4.128 (P = 0.248). HR: hazard rate, CI: confidence interval.
Figure 3
Figure 3
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which ATAC trial was excluded. Test for heterogeneity (Q) = 0.490 (P = 0.783). HR: hazard rate, CI: confidence interval.
Figure 4
Figure 4
Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were included.aFor ATAC trial, HR for recurrence free survival of estrogen receptor positive patients was included in the model. Test for heterogeneity (Q) = 2.244 (P = 0.523). HR: hazard rate, CI: confidence interval.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717. doi: 10.1016/S0140-6736(05)66544-0. - DOI - PubMed
    1. Dorssers LC, Flier S Van der, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs. 2001;61:1721–33. doi: 10.2165/00003495-200161120-00004. - DOI - PubMed
    1. Gradishar WJ. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology. 2005;69:1–9. doi: 10.1159/000087282. - DOI - PubMed
    1. Arimidex , Tamoxifen , Alone or in Combination (ATAC) Trialists' Group. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi: 10.1016/S1470-2045(07)70385-6. - DOI - PubMed
    1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–9. doi: 10.1016/S0140-6736(02)09088-8. - DOI - PubMed

LinkOut - more resources